Intended for healthcare professionals


Gene therapy experiments put on “clinical hold”

BMJ 2000; 320 doi: (Published 05 February 2000) Cite this as: BMJ 2000;320:336
  1. James Ciment
  1. New York

    The Food and Drug Administration (FDA) temporarily shut down a series of human gene therapy experiments at the University of Pennsylvania last month following the death of Jesse Gelsinger, an 18 year old man from Arizona who was being treated for a liver disorder.

    The order to place the university's entire gene therapy programme on indefinite “clinical hold” came two days after inspectors issued a report noting 18 specific violations of government protocols.

    The administration said …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription